PDCD1 and non-small cell lung carcinoma: These compounds were further selected by using the following criteria in the CCLE NSCLC panel (n = 117): (1) choosing the small molecules with strong inhibitory effects of NSCLC cells, i.e., with low IC50 and EC50 values, and (2) filtering the compounds with a negative correlation of drug concentration and mRNA expression of CD27, PD1, or PDL1 in the NSCLC cell lines.